1.
Clin Ter
; 127(2): 113-8, 1988 Oct 31.
Artigo
em Italiano
| MEDLINE
| ID: mdl-2976346
2.
Haematol Blood Transfus
; 30: 315-21, 1987.
Artigo
em Inglês
| MEDLINE
| ID: mdl-3623239
RESUMO
Seven patients were treated with low dose Ara-C (LDAC). Five patients had acute nonlymphoid leukemia (ANLL), two patients had myelodisplastic syndrome (MDS): refractory anemia (RA) and refractory anemia with excess of blasts in transformation (RAEB-t). Ara-C treatment was given by s.c. injections at a dose of 10-11 mg/m2 every 12 h and only on two occasions by continuous infusion. No improvement, or limited improvement, was observed in five patients and they died of leukemia or of disease-related complications. Two patients with ANLL achieved remission: the first patient after bone marrow aplasia, the second without aplasia but with morphologic evidence of granulocytic differentiation of leukemic cells.